Tina Reed on Axios
Access is unequal to weight-loss drugs Ozempic and Wegovy: study
Prescriptions for blockbuster drugs that treat diabetes, obesity and heart disease are soaring, but the mix of payers shows access to the drugs is far from equitable, per a study published in JAMA Health Forum. The USC-led study found a 442% increase in scripts for semaglutide — the active ingredient in diabetes drug Ozempic and anti-obesity and heart disease drug Wegovy — between January 2021 and December 2023. Less than 30% of Ozempic prescriptions and only 1.2% of Wegovy prescriptions were filled for patients on Medicare Part D plans.
Read more here